Success examples
In Vitro and In Vivo Behaviors of KinetiSol and Spray-Dried Amorphous Solid Dispersions of a Weakly Basic Drug and Ionic Polymer

Jermain S. V., Lowinger M. B., Ellenberger D. J., Miller D. A., Su Y., Williams III R. O.

Mol. Pharmaceutics 2020, 17, 8, 2789-2808.

CCR1 antagonist
DOI
PUBMED
Success examples
Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements

Hiroyoshi Y. T., Tsuyoshi K., Takuya N., Michiya M., Atsushi M., Mitsunobu R.K.

Biomaterials 2020, 251:120077.

GSK-3 inhibitor
DOI
PubMed
Success examples
Mechanistic MALDI-TOF Cell-Based Assay for the Discovery of Potent and Specific Fatty Acid Synthase Inhibitors

Weigt D., Parrish CA., Krueger JA., Oleykowski CA., Rendina AR., Hopf C.

Cell Chemical Biology 2019, 26, 1322-1331 E4. open access

FAS inhibitor
DOI
PUBMED
Success examples
Impedance-based analysis of Natural Killer cell stimulation

Fasbender F., Watzl C.

Scientific Reportsvolume 8, Article number: 4938 (2018)

LFA-1 antagonist
DOI
PubMed
Success examples
Identification of novel azaindazole CCR1 antagonist clinical candidates

Harcken C., Kuzmich D., Cook B., Mao C., Disalvo D., Razavi H., Swinamer A., Liu P., Zhang Q., Kukulka A., Skow D., Patel M., Patel M., Fletcher K., Sherry T., Joseph D., Smith D., Canfield M., Souza D., Bogdanffy M., Berg K., Brown M.

Bioorganic & Medicinal Chemistry Letters 2019, 29, 441-448.

CCR1 antagonist
DOI
PubMed